Researchers across 14 medical centers in China, including Peking University People’s Hospital, have found that an investigational drug, berberine ursodeoxycholate (HTD1801), significantly lowered blood sugar levels and improved metabolic and liver health in patients with type 2 diabetes (T2D). The findings and an invited commentary, both published in JAMA Network Open, suggest that HTD1801 could serve as a new oral treatment option for T2D and its related complications.